Spruce Biosciences recently announced that its candidate drug TA-ERT for Sanfilippo syndrome type B (also known as MPS IIIB) received positive feedback during a Type B meeting with the U.S. Food and Drug Administration (FDA).

Spruce Biosciences recently announced that its candidate drug TA-ERT for Sanfilippo syndrome type B (also known as MPS IIIB) received positive feedback during a Type B meeting with the U.S. Food and Drug Administration (FDA).

老虎证券2026/02/18 12:16

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

The meeting focused on discussing the clinical development plan for the drug. Both parties reached an important consensus on the subsequent trial protocol, laying a solid foundation for advancing the research and development process of TA-ERT.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Spruce Biosciences recently announced that its candidate drug TA-ERT for Sanfilippo syndrome type B (also known as MPS IIIB) received positive feedback during a Type B meeting with the U.S. Food and Drug Administration (FDA).

You may also like

Crypto prices